Background/Aims: The streptomycete derived farnesyltransferase inhibitor Manumycin A triggers apoptosis of tumor cells and is thus considered for the treatment of malignancy. The present study explored whether Manumycin A could similarly stimulate eryptosis, the suicidal death of erythrocytes characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Stimulators of eryptosis include Ca 2+ entry as well as activation of staurosporine sensitive protein kinase C and SB203580 sensitive p38 kinase. The present study explored, whether Manumycin A induces eryptosis and, if so, to shed some light on the mechanisms involved. Methods: Phosphatidylserine abundance at the human erythrocyte surface was estimated from annexin-V-binding, cell volume from forward scatter, and hemolysis from hemoglobin concentration in the supernatant. Results: A 48 hours exposure of human erythrocytes to Manumycin A (≥ 5 µg/ml) significantly increased the percentage of annexin-V-binding cells, significantly decreased forward scatter and significantly incrased hemolysis. The effect of Manumycin A on annexin-V-binding was significantly blunted by removal of extracellular Ca 2+ , by addition of staurosporine (1 µM) and by addition of SB203580 (2 µM). Conclusions: Manumycin A triggers hemolysis, cell shrinkage and phospholipid scrambling of the human erythrocyte cell membrane. The effect on cell membrane scrambling was in part but not fully dependent on entry of extracellular Ca 2+ , as well as activity of staurosporine and SB203580 sensitive kinases.
Introduction
The natural antibiotic [1] [2] [3] [4] [5] Manumycin A is a streptomycete derived farnesyltransferase inhibitor [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , Manumycin A downregulates the release of proinflammatory cytokines and thus counteracts inflammation [7] as well as atherosclerosis [3] . Moreover, manumycin A corrects aberrant splicing of the chloride channel Clcn1 and may thus be effective in the treatment of myotonic dystrophy type 1 [16] . Manumycin A triggers suicidal death of tumor cells [9, 10, 12, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and the substance is effective against diverse malignancies [6, 8, [17] [18] [19] [20] [21] [22] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Mechanisms involved in Manumycin A induced apoptosis include inhibition of Ras [5, 6, 8, 11, 13-15, 26, 27, 29, 33] , HIF-1α [8] , and IkappaB kinase (IKK) [24, 32] , activation of the mitochondrial apoptotic pathway [17, 21, 23] , oxidative stress [18, 20, 22, 30, 31] , as well as activation of caspases [9, 19, 23] .
Similar to apoptosis of nucleated cells, erythrocytes may enter eryptosis, the suicidal death of erythrocytes characterized by cell shrinkage [36] and cell membrane scrambling with phosphatidylserine translocation to the cell surface [37] . Triggers of eryptosis include Ca 2+ entry with increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ) [37] , as well as activation of protein kinase C or of p38 kinase [37] . Eryptosis is elcited by a wide variety of xenobiotics .
The present study explored, whether exposure of human erythrocytes to Manumycin A stimulates eryptosis. To this end, erythrocytes isolated from healthy volunteers were treated with Manumycin A and cell volume, phosphatidylserine surface abundance, as well as hemolysis quantified.
Materials and Methods

Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl 2 , at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to Manumycin A (Enzo Life Sciences, Lörrach, Germany). To test for an involvement of p38 kinase, erythrocytes were exposed for 48 hours to a combination of Manumycin A and p38 kinase inhibitor SB 203580 (Tocris bioscience, Bristol, UK). To test for an involvement of protein kinase C, erythrocytes were exposed for 48 hours to a combination of Manumycin A and staurosporine (Sigma Aldrich, Hamburg, Germany).
Annexin-V-binding and forward scatter
After incubation under the respective experimental condition, a 100 µl cell suspension was washed in Ringer solution containing 5 mM CaCl 2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 20 min under protection from light. The annexin-Vabundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, Germany). Annexin-V-binding was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding cells and control cells. The same threshold was used for untreated and Manumycin A treated erythrocytes. A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both parameters. The threshold of forward scatter was set at the default value of "52".
Intracellular Ca
2+
After incubation, erythrocytes were washed in Ringer solution and loaded with Fluo-3/AM (Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl 2 and 5 µM Fluo-3/AM. The cells were incubated at 37°C for 30 min. Ca 
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.
Results
The present study explored whether Manumycin A stimulates eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and by phospholipid scrambling of the cell membrane with phosphatidylserine translocation to the cell surface. To this end, the erythrocytes were incubated for 48 hours in Ringer solution without or with Manumycin A (1 -10 µg/ml).
Erythrocyte volume was estimated from forward scatter which was determined utilizing flow cytometry. As illustrated in Fig. 1 , Manumycin A decreased erythrocyte forward scatter, an effect reaching statistical significance at 5 µg/ml Manumycin A concentration. Along those lines treatment of erythrocytes with Manumycin A was followed by a significant increase of the percentage of shrunken erythrocytes (Fig. 1C) , an effect reaching statistical significance at 5 µg/ml Manumycin A concentration. Manumycin A treatment simultaneously increased the percentage of swollen erythrocytes, an effect reaching statistical significance at 10 µg/ ml Manumycin A concentration (Fig. 1D) .
The percentage of hemolytic erythrocytes was estimated from the hemoglobin concentration in the supernatant. As illustrated in Fig. 2 , a 48 hours exposure to Manumycin A 
increased the percentage of hemolytic erythrocytes, an effect reaching statistical significance at 5 µg/ml Manumycin A. Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding, as determined by flow cytometry. As illustrated in Fig. 3, a 48 To explore, whether the effects of Manumycin A involved protein kinase C and/or p38 kinase activity, the influence of Manumycin A on annexin-V-binding was tested in the absence or presence of protein kinase C inhibitor staurosporine (1 µM) or p38 kinase inhibitor SB 203580 (2 µM). As illustrated in Fig. 5 , both staurosporine and SB203580 significantly 
Discussion
The present observations uncover a novel effect of Manumycin A, i.e. the triggering of eryptosis, the suicidal erythrocyte death. Exposure of erythrocytes from healthy individuals with Manumycin A was followed by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. The concentrations required for those effects were in the range of plasma concentrations determined in Manumycin A treated mice [69] and may thus be clinically relevant. Erythrocytes may be particularly sensitive to the proeryptotic effect of Manumycin A in clinical conditions with accelerated eryptosis, such as dehydration [70] , hyperphosphatemia [71] , chronic kidney disease (CKD) [72] [73] [74] [75] , hemolytic-uremic syndrome [76] , diabetes [77] , hepatic failure [78] , malignancy [37] , sepsis [79] , sickle-cell disease [37] , beta-thalassemia [37] , Hb-C and G6PD-deficiency [37] , as well as Wilsons disease [80] .
Interference , the drug was effective in part by mechanisms other than Ca 2+ entry. Additional mechanisms apparently effective were activation of staurosporine and SB203580 sensitive kinases which have previously been shown to trigger eryptosis [37] .
Eryptotic erythrocytes are rapidly cleared from circulating blood [37] . Thus eryptosis of defective erythrocytes may precede and thus prevent hemolysis with release of hemoglobin, which passes the renal glomerular filter, precipitates in the acidic lumen of renal tubules, occludes nephrons and thus may lead to renal failure [81] . Eryptosis is triggered by infection with the malaria pathogen Plasmodium and serves to remove infected erythrocytes from circulation [37] .
The removal of phosphatidylserine exposing erythrocytes from circulating blood results in anemia as soon as the loss of erythrocytes exceeds the formation of new erythrocytes by erythropoiesis [37] . Phosphatidylserine exposing erythrocytes further adhere to the vascular wall [82] , stimulate blood clotting and foster thrombosis [83] [84] [85] . Triggering of eryptosis may thus compromise microcirculation [83, [86] [87] [88] [89] [90] .
In conclusion, Manumycin A triggers eryptosis with cell shrinkage and cell membrane scrambling, an effect in part dependent on Ca 2+ entry and activation of staurosporine and SB203580 sensitive kinases.
